Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.

Here's Why Adverum Biotechnologies  Is Soaring Today

-- Robust efficacy with evidence of a dose response --  -- 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks --   -- 4/6 patients rescue-injection-free in cohort 2 (lower dose) at 24 weeks --    -- Company to host and webcast a discussion with key opinion leaders  Sunday, February 9, at 10:00 am EST --

Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020

- New headquarters includes 80,000 square feet of office, laboratory, and manufacturing space to advance the development of Adverum’s novel gene therapies -

Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA

Adverum Biotechnologies: Keep On Your Watchlist In 2020

-- OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20 --    -- IND application planned for ADVM-022 in diabetic retinopathy in 1H20; Patient enrollment targeted for 2H20 --

Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook

--44 week median follow up for patients (n=6)--  --Zero anti-VEGF rescue injections required following intravitreal ADVM-022; First patient has reached 52-weeks post treatment--  --Vision remains stable and anatomical improvements maintained--  MENLO PARK, Calif., Jan.  11, 2020  (GLOBE NEWSWIRE) --  Adverum Biotechnologies, Inc.  (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, the company’s intravitreal injection gene therapy, in treatment-experienced patients with wet age-related macular degeneration (wet AMD). The data are being presented today by Charles C. Wykoff M.D., Ph.D., director of research, Retina Consultants of Houston, at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting in New York, NY.

Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting

Cara Therapeutics

Green Dot

Innovative Industrial Properties

iShares Russell 2000 ETF

MFAM Small-Cap Growth ETF

SPDR S&P 500 ETF Trust

Vanguard S&P Small-Cap 600 ETF

Small-cap stocks have been subpar performers of late, but that weakness has only made the opportunity more compelling.

Why Your 2020 Resolution Should Be to Buy More Small-Cap Stocks

ArQule

Arrowhead Pharmaceuticals

Here's how they could keep on rocketing higher.

3 Soaring Biotech Stocks to Watch in December

Adverum Biotechnologies, Inc. (ADVM) CEO Leone Patterson on Q3 2019 Results - Earnings Call Transcript

MENLO PARK, Calif., Oct.  30, 2019  (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of seasoned life sciences executive Peter Soparkar as chief legal officer. Most recently, Mr. Soparkar served as chief legal officer and head of human resources at Counsyl, Inc., prior to the company’s sale to Myriad Genetics and spent 10 years at Jazz Pharmaceuticals, most recently as their vice president and associate general counsel.

Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer

Advanced Micro Devices

Patients in the Third Cohort of OPTIC will Receive a Single ADVM-022 Dose of 2 x 10 ^11 vg/eye Patients in the Third Cohort of OPTIC will Receive a Single ADVM-022 Dose of 2 x 10 ^11 vg/eye

Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

-- Szilárd Kiss, M.D. to present an encore presentation of data from first cohort of the OPTIC phase 1 trial of ADVM-022 in wet AMD --  MENLO PARK, Calif., Oct.  23, 2019  (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations on the company’s gene therapy programs to be presented at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress in Barcelona, Spain.

Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress

-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with  median follow up of 34 weeks -- -- Sequential enrollment planned for OPTIC third and fourth cohorts --  -- Company to host and webcast a discussion with key opinion leaders on  Saturday, October 12 at 10:30 am PT --  MENLO PARK, Calif., Oct.  11, 2019  (GLOBE NEWSWIRE) --  Adverum Biotechnologies, Inc.  (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced additional clinical data for the first cohort of patients (n=6) in the ongoing OPTIC phase 1 clinical trial of ADVM-022, the company’s intravitreal injection gene therapy, in treatment-experienced patients with wet age-related macular degeneration (wet AMD). The data are being presented today during a podium presentation at the Retina Subspecialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA. In addition, Adverum will host a discussion with key opinion leaders on Saturday, October 12, 2019 at 10:30 am PT, which will be webcast live and archived on the  Events and Presentations  section of the company’s website.

Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

Kodiak Sciences Inc

REGENXBIO

Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.

3 Blindness-Fighting Biotech Stocks That Could Surge This Week

Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Adverum Biotechnologies Enters Oversold Territory

Company to Host and Webcast a Discussion with Key Opinion Leaders on Saturday, October 12 at 10:30 am PT Company to Host and Webcast a Discussion with Key Opinion Leaders on Saturday, October 12 at 10:30 am PT

Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why

Adverum Biotechnologies Trade Derisked After Huge Price Drop

Duluth Hlds

Tailored Brands

Even on an up day for the stock market, these companies lost a lot of ground.

Why Duluth Holdings, Tailored Brands, and Adverum Biotechnologies Slumped Today

The biotech’s gene therapy isn’t helping patients see better.

Here's Why Adverum's Shares Saw a Lower Price Today

Adverum Biotechnologies Inc (NASDAQ: ADVM) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference.

Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial

-- Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 --    -- Sustained improvements in retinal anatomy --

Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

Adverum Biotechnologies, Inc. (ADVM) CEO Leone Patterson on Q2 2019 Results - Earnings Call Transcript

Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy?

Shares have staged an impressive feedback thus far in 2019, rising over 350% since the beginning of the year.

News for Adverum Biotechnologies Stock (ADVM)